Clinical trial · Interventional
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
NCT03657017CI-TRIAL-00034681unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
| PET/MR | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/MR | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- PET/MR
- description
- Patients are examined with PET/MR.
- interventionNames
- Diagnostic Test: PET/MR
Primary outcomes (1)
- measure
- Multiparametric PET/MRI-based radiomics nomograms for locally advanced nasopharyngeal carcinoma
- timeFrame
- From day 1 of chemotherapy to the date of the event, a minimum follow-up of 3 years.
- description
- Radiomics-based prognostic model by PET/MRI
Secondary outcomes (1)
- measure
- Prediction model of the efficiency of treatment in locally advanced nasopharyngeal carcinoma
- timeFrame
- about 4 years (all of patients complete treatment)
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with newly histologically confirmed non-keratinizing carcinoma. * Tumor staged T1-4N0-3M0 （according to the 8th AJCC staging system） * Performance status: KPS\>70 * With normal liver function test (ALT, AST \<1.5ULN) * Renal: creatinine clearance \>60ml/min * Without hematopathy,marrow: WBC \>4\*109/L, HGB\>80G/L, and PLT\>100\*109/L. * Written informed consent Exclusion Criteria: * Adenocarcinoma * Age \>70 * Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) * Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) * Patient is pregnant or lactating * Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), or emotional disturbance.
References
Publications (0)
Data not yet available
No reference posted for this study.